# ERBB2 (HER2): Extracellular Domain Amplification, Heterodimerization, and Antibody-Drug Conjugates


## Key Takeaways

- ERBB2 (HER2) is a type I transmembrane receptor tyrosine kinase that lacks a direct ligand but functions as a crucial heterodimerization partner for other ErbB family members, amplifying downstream signaling pathways like RAS-MAPK and PI3K-AKT, which drive cell proliferation and survival.
- ERBB2 gene amplification is a primary oncogenic driver in breast and gastric cancers, leading to protein overexpression and serving as a key diagnostic indicator for targeted therapies, including monoclonal antibodies (trastuzumab, pertuzumab) and antibody-drug conjugates (T-DM1, T-DXd).
- Activating mutations in ERBB2, particularly in the extracellular domain (e.g., S310F/Y) and kinase domain (e.g., L755S, V777L), can promote constitutive receptor dimerization and signaling, conferring sensitivity to specific tyrosine kinase inhibitors (TKIs) like neratinib and tucatinib.
- Clinical assessment of ERBB2 status relies on a dual immunohistochemistry (IHC) and in situ hybridization (ISH) algorithm, with HER2-low status (IHC 1+ or 2+ without amplification) now recognized as a predictive biomarker for certain ADCs.
- ERBB2 plays a critical role in normal cardiac development, and its targeted inhibition can lead to cardiotoxicity, necessitating careful monitoring during therapy.
- Pharmacogenomic considerations, including ERBB2 copy number, mRNA expression, and the presence of specific mutations, alongside pathway alterations (e.g., PI3K/AKT) and tumor microenvironment factors, influence the efficacy and resistance mechanisms of HER2-targeted agents.

---

## Executive Summary & Key Metadata

The ERBB2 gene (also known as HER2, HER2/neu, or c-erbB-2) encodes a 185-kDa type I transmembrane receptor tyrosine kinase (RTK) belonging to the epidermal growth factor receptor (EGFR/ErbB) family. Unlike its paralogs EGFR (ERBB1), ERBB3, and ERBB4, ERBB2 has no known high-affinity soluble ligand; instead, it functions as the preferred heterodimerization partner for all other ErbB family members, amplifying and diversifying downstream signaling. ERBB2 is a master oncogene in multiple solid tumors, most notably breast and gastric cancers, where gene amplification and protein overexpression drive aggressive tumor phenotypes. The clinical management of ERBB2-driven cancers has been revolutionized by targeted therapies, including the monoclonal antibody trastuzumab, the tyrosine kinase inhibitors (TKIs) lapatinib, neratinib, and tucatinib, and the antibody-drug conjugates (ADCs) ado-trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd). This reference manual provides a comprehensive, publication-grade overview of ERBB2, covering its genomic architecture, structural biology, signaling networks, pathogenic mutations, [pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), and bioinformatic resources.

| **Attribute** | **Value** |
| :--- | :--- |
| **HGNC Symbol** | ERBB2 |
| **UniProt Accession** | P04626 |
| **Representative PDB ID** | 1N8Z |
| **Chromosomal Locus** | 17q12 (17q11.2-q12) [1, 2] |
| **Primary Molecular Function** | Receptor tyrosine kinase; signal transduction; cell proliferation, differentiation, and survival |
| **Disease & Pathology Associations** | Breast cancer, gastric/gastroesophageal cancer, lung cancer, gynecologic malignancies, salivary duct carcinoma, and others [1, 3, 4, 5, 6, 7, 8, 9] |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The ERBB2 gene is located on the long arm of human chromosome 17 at cytogenetic band 17q12, a region historically designated 17q11.2-q12 [1, 2]. The gene spans approximately 40 kilobases (kb) of genomic DNA and comprises 27 exons, with the coding sequence distributed across exons 2 through 27. The genomic coordinates (GRCh38/hg38) are approximately chr17:39,687,914-39,728,658 (minus strand). The ERBB2 locus resides within a gene-dense region that includes GRB7, a downstream signaling adaptor frequently co-amplified with ERBB2 in breast cancer, and the TOP2A gene, which encodes topoisomerase IIα, a target of anthracycline chemotherapy [1, 10, 11].

### 1.2 Promoter Architecture and Transcriptional Regulation

The ERBB2 promoter is a TATA-less, GC-rich promoter that contains multiple cis-acting regulatory elements. Key transcription factor binding sites include those for the activator protein-2 (AP-2) family, which are critical for basal and induced ERBB2 expression. A specific AP-2 binding site, termed the HTF (HER2 transcription factor) binding site, has been identified as a major determinant of ERBB2 overexpression in breast cancer cells [12]. The promoter also contains binding sites for the ETS family of transcription factors, SP1, and the PEA3 subfamily. The transcription factor LMO4 (LIM domain only 4) has been shown to be an essential mediator of ErbB2-induced cell cycle progression, acting downstream of ERBB2 signaling to regulate the expression of genes involved in proliferation [13].

### 1.3 Enhancer Elements and Epigenetic Regulation

ERBB2 expression is modulated by distal enhancer elements and epigenetic modifications. Chromatin conformation capture studies have revealed long-range interactions between the ERBB2 promoter and enhancer regions located within the gene desert upstream of the locus. DNA methylation patterns within the ERBB2 promoter and gene body are altered in gastrointestinal cancers, with tumor-specific hypomethylation correlating with increased expression [14]. Global reduction of H3K27me3, a repressive histone mark, has been shown to enhance the efficacy of HER2-targeted therapy, suggesting that epigenetic state influences both ERBB2 expression and therapeutic response [15].

### 1.4 Alternative Splicing and Isoforms

The canonical ERBB2 transcript encodes the full-length 1,255-amino acid receptor. Alternative splicing events generate several minor isoforms, including a soluble, truncated extracellular domain (ECD) variant that can be detected in patient serum. This shed ECD is generated by proteolytic cleavage of the full-length receptor by matrix metalloproteinases (MMPs) and the α-secretase ADAM10, rather than by alternative splicing. A naturally occurring splice variant lacking exon 16 (Δ16HER2) has been described; this isoform promotes constitutive, ligand-independent homodimerization and is associated with enhanced oncogenic signaling and trastuzumab resistance. The Δ16HER2 isoform is characterized by the deletion of a 16-amino acid region within the extracellular domain subdomain II, which is the dimerization arm [16].

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Topology

The ERBB2 protein is a single-pass type I transmembrane glycoprotein of 1,255 amino acids, organized into three principal domains: a large N-terminal extracellular domain (ECD, residues 1-652), a single hydrophobic transmembrane helix (residues 653-675), and an intracellular region (residues 676-1255) comprising a juxtamembrane segment, a bilobal tyrosine kinase domain, and a flexible C-terminal tail containing multiple autophosphorylation sites.

### 2.2 Extracellular Domain (ECD)

The ECD is composed of four subdomains (I-IV) arranged in a tandem repeat of two homologous modules. Subdomains I (residues 1-165) and III (residues 274-480) are homologous to the ligand-binding domains of EGFR. However, in ERBB2, these subdomains are in a "closed" conformation that precludes ligand binding. Subdomain II (residues 166-273) contains a critical β-hairpin loop, known as the dimerization arm, which is constitutively exposed. This exposed arm enables ERBB2 to be the preferred heterodimerization partner for ligand-bound EGFR, ERBB3, or ERBB4. Subdomain IV (residues 481-652) contains a cysteine-rich region and interacts intramolecularly with subdomain II in the "tethered" conformation of other ErbB receptors; in ERBB2, this tethering interaction is absent, locking the receptor in an active, extended conformation [16]. The ECD is the target of the therapeutic monoclonal antibodies trastuzumab and pertuzumab, which bind to distinct epitopes on subdomain IV and subdomain II, respectively.

### 2.3 Transmembrane and Intracellular Domains

The transmembrane domain is a single α-helix that mediates receptor dimerization through specific GxxxG-like motifs. The intracellular juxtamembrane region (residues 676-720) contains a nuclear localization signal and a calmodulin-binding site. The tyrosine kinase domain (residues 721-987) adopts the canonical bilobal architecture of RTKs: an N-terminal lobe (N-lobe) composed of a five-stranded β-sheet and a single α-helix, and a larger C-terminal lobe (C-lobe) rich in α-helices. The ATP-binding cleft is located between the two lobes. The activation loop (A-loop) within the kinase domain is constitutively phosphorylated at tyrosine 877 (Y877), which stabilizes the active conformation of the kinase. The C-terminal tail (residues 988-1255) contains several tyrosine residues (Y1023, Y1139, Y1196, Y1221/1222, and Y1248) that, upon phosphorylation, serve as docking sites for downstream signaling proteins containing Src homology 2 (SH2) or phosphotyrosine-binding (PTB) domains.

### 2.4 Structural Basis of Activation

ERBB2 activation is driven by receptor overexpression and/or heterodimerization. In the absence of a ligand, ERBB2 can form homodimers when expressed at high density on the cell surface, leading to constitutive kinase activation. More commonly, ERBB2 forms heterodimers with ligand-occupied EGFR, ERBB3, or ERBB4. The kinase domain of ERBB2 can also be activated by oncogenic mutations, particularly in the ECD (e.g., S310F/Y) and the kinase domain (e.g., L755S, V777L, V842I), which promote constitutive dimerization and signaling [1, 2, 8, 17, 18].

> **[Interactive 3D Protein Visualizer: Load ERBB2 (PDB: 1N8Z)](/tools/protein-structure-viewer?source=direct&pdbId=1N8Z)**

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The ErbB Signaling Network

ERBB2 is a central node in the ErbB signaling network. Upon heterodimerization with a ligand-bound ErbB receptor, the intracellular kinase domains transphosphorylate specific tyrosine residues on the C-terminal tail of the partner receptor. These phosphotyrosine residues create docking sites for a variety of adaptor proteins and enzymes, initiating a cascade of intracellular signaling pathways.

### 3.2 Downstream Signaling Cascades

The principal downstream pathways activated by ERBB2 include:

- **RAS-MAPK Pathway**: The GRB2-SOS complex is recruited to phosphotyrosine residues, leading to RAS activation and subsequent activation of the RAF-MEK-ERK cascade. This pathway drives cell proliferation and differentiation. The dual-specificity phosphatase DUSP6, a negative regulator of ERK signaling, is downregulated in ERBB2-overexpressing cells, contributing to sustained pathway activation [3].
- **PI3K-AKT-mTOR Pathway**: ERBB2 directly binds to the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K) via its YXXM motifs, or indirectly through ERBB3, which has multiple p85 binding sites. This leads to the generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and activation of AKT, a master regulator of cell survival, growth, and metabolism. The tumor suppressor PTEN negatively regulates this pathway.
- **JAK-STAT Pathway**: ERBB2 can activate signal transducer and activator of transcription (STAT) proteins, particularly STAT3, which translocates to the nucleus to regulate genes involved in cell cycle progression and survival.
- **PLCγ-PKC Pathway**: Phospholipase C-γ (PLCγ) binds to specific phosphotyrosine residues and hydrolyzes PIP2 to generate diacylglycerol (DAG) and inositol trisphosphate (IP3), leading to protein kinase C (PKC) activation and calcium release.

### 3.3 Regulatory Feedback Loops

ERBB2 signaling is subject to multiple layers of negative regulation. The E3 ubiquitin ligase CBL is recruited to activated ERBB2, leading to receptor ubiquitination, endocytosis, and lysosomal degradation. However, ERBB2 is internalized at a slower rate than other ErbB receptors, and its high-level expression can saturate the endocytic machinery, leading to prolonged signaling. The protein tyrosine phosphatases PTPN2 and PTPN12 dephosphorylate ERBB2, attenuating signaling. Loss of PTPN2 expression or function is associated with trastuzumab resistance [4]. Additionally, the mRNA stability of ERBB2 and its downstream targets is regulated by AU-rich elements (AREs) and ARE-binding proteins, providing a post-transcriptional layer of control [5].

### 3.4 Protein-Protein Interaction Networks

ERBB2 engages in a complex network of protein-protein interactions. The adaptor protein GRB7, which is co-amplified with ERBB2, binds directly to the receptor and promotes cell migration and invasion. The transcriptional regulator LMO4 is a downstream effector of ERBB2 signaling, essential for cell cycle progression [13]. The huntingtin protein (HTT) has been shown to interact with ERBB2 signaling, accelerating breast tumor development and metastasis [6]. The microRNA miR-125b targets erythropoietin and its receptor, and its expression correlates with ERBB2/HER2 expression and metastatic potential, indicating a complex regulatory network involving non-coding RNAs [7]. Circular RNA circ-ERBB2, derived from the ERBB2 gene locus, promotes HER2-positive breast cancer progression by sponging miR-136-5p and miR-198 [8].

### 3.5 Role in Normal Physiology

Beyond its oncogenic roles, ERBB2 is critical for normal cardiac development and function. Conditional knockout of ErbB2 in mouse cardiomyocytes leads to dilated cardiomyopathy, highlighting its essential role in maintaining cardiac structure and function [9]. This finding underpins the cardiotoxicity observed with HER2-targeted therapies, particularly trastuzumab. ERBB2 signaling is also involved in the development of the peripheral nervous system and mammary gland.

```mermaid
sequenceDiagram
    participant L as "Ligand (e.g., NRG1)"
    participant R3 as "ERBB3"
    participant R2 as "ERBB2"
    participant K as "Kinase Domain (ERBB2)"
    participant A as "Adaptor Proteins (GRB2, p85)"
    participant P as "Downstream Pathways (RAS-MAPK, PI3K-AKT)"
    L->>R3: Binds
    R3->>R2: Heterodimerization
    R2->>K: Conformational change & transphosphorylation
    K->>A: Recruits SH2/PTB domain proteins
    A->>P: Activates signaling cascades
    P-->>R2: Negative feedback (e.g., DUSP6, PTEN)
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 ERBB2 Amplification

Gene amplification is the most common oncogenic alteration of ERBB2. Amplification leads to a dramatic increase in ERBB2 copy number and protein overexpression on the cell surface. This is a defining feature of HER2-positive breast cancer (15-20% of cases) and is also observed in gastric, gastroesophageal, ovarian, endometrial, salivary duct, and other cancers [1, 3, 4, 6, 7, 9, 10]. The level of amplification, as measured by ERBB2 copy number, is a predictive biomarker for the efficacy of trastuzumab in HER2-positive advanced esophagogastric and gastric cancer [11]. ERBB2 amplification can be heterogeneous within a tumor, and its status can change after chemotherapy, leading to diagnostic pitfalls [12, 13]. In breast cancer, ERBB2 amplification is associated with the HER2-enriched (HER2-E) intrinsic subtype, as defined by the PAM50 gene expression assay [1, 14].

### 4.2 Activating Mutations

In addition to amplification, ERBB2 is subject to recurrent somatic mutations that drive oncogenesis. These mutations are found across a wide variety of cancers, including breast, lung, gastric, colorectal, bladder, and gynecologic malignancies [1, 4, 8, 15, 17, 18].

- **Extracellular Domain (ECD) Mutations**: The most common ECD mutations are S310F and S310Y, which are frequently found in micropapillary urothelial carcinoma and other tumor types [18]. These mutations promote constitutive receptor dimerization and activation, independent of ligand.
- **Kinase Domain Mutations**: Mutations in the kinase domain, such as L755S, V777L, V842I, and L755P, are recurrent in various cancers [2, 17]. The L755S mutation is a well-characterized resistance mechanism to lapatinib, while V777L and V842I are activating mutations that confer sensitivity to neratinib and other irreversible TKIs. These mutations can occur concurrently with gene amplification [16].
- **Transmembrane Domain Mutations**: Mutations such as V659E and G660D in the transmembrane domain have been identified and are predicted to promote receptor dimerization.

### 4.3 Germline Variants

Germline coding variants in ERBB2 have been associated with an increased risk of myeloproliferative neoplasms (MPN) [17]. The common polymorphism Ile655Val has been extensively studied for its association with breast cancer risk, though results have been inconclusive [18].

### 4.4 Gene Fusions

ERBB2 gene fusions are rare but recurrent events across multiple tumor types, including breast, lung, and colorectal cancers [1, 2]. These fusions typically involve the ERBB2 kinase domain fused to various N-terminal partners, leading to constitutive kinase activation. The clinical significance and therapeutic targeting of ERBB2 fusions are areas of active investigation.

### 4.5 Clinical Differentials and Diagnostic Testing

The clinical assessment of ERBB2 status is critical for therapeutic decision-making. Standard guidelines (ASCO/CAP) recommend a dual algorithm of immunohistochemistry (IHC) for protein expression and in situ hybridization (ISH) for gene amplification [3, 4, 5]. Tumors are classified as HER2-positive if they show IHC 3+ (strong, complete, circumferential membranous staining) or IHC 2+ with ERBB2 amplification by ISH. The definition of HER2-low (IHC 1+ or IHC 2+ without amplification) has gained clinical importance with the advent of ADCs like T-DXd, which show activity in this subgroup [6, 7, 8]. ERBB2 mRNA expression levels, as measured by quantitative PCR or RNA-seq, can also be used to assess ERBB2 status [9, 10]. Next-generation sequencing (NGS) is increasingly used to detect ERBB2 mutations, fusions, and copy number alterations in a single assay [1, 11].

## 5. Host-Pathogen & Viral Interactions (If applicable)

ERBB2 does not have a well-characterized role as a direct receptor for viral or bacterial pathogens. However, several indirect interactions have been reported:

- **Viral Oncoproteins**: The human papillomavirus (HPV) E6 and E7 oncoproteins have been shown to upregulate ERBB2 expression in cervical cancer cells, contributing to the frequent amplification of ERBB2 observed in squamous cell carcinoma of the uterine cervix [12].
- **Immune Evasion**: ERBB2 overexpression can modulate the tumor immune microenvironment. The ectonucleotidase CD73, which generates immunosuppressive adenosine, promotes resistance to HER2 antibody therapy, suggesting a link between ERBB2 signaling and immune evasion [13]. Carbonic anhydrases, which regulate tumor pH, also influence immune infiltration and prognosis in ERBB2-enriched breast cancer [14].
- **CAR-Engineered Immune Cells**: ERBB2 is a target for chimeric antigen receptor (CAR)-engineered immune cells. CAR-macrophages targeting ERBB2 have been developed for the locoregional treatment of brainstem glioma [15]. Bispecific killer cell engagers (BiKEs) directed against EGFR and ERBB2 have been used to enhance the elimination of glioblastoma cells by NKG2D-CAR-engineered NK cells [16].

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 Monoclonal Antibodies

- **Trastuzumab**: A humanized monoclonal antibody that binds to subdomain IV of the ERBB2 ECD. It inhibits ERBB2 signaling, induces antibody-dependent cell-mediated cytotoxicity (ADCC), and promotes receptor internalization and degradation. Trastuzumab is approved for the treatment of HER2-positive breast and gastric cancers [1, 11, 14, 17, 18].
- **Pertuzumab**: A humanized monoclonal antibody that binds to subdomain II of the ERBB2 ECD, sterically hindering heterodimerization with other ErbB receptors. It is used in combination with trastuzumab and chemotherapy for HER2-positive breast cancer.
- **Trastuzumab Emtansine (T-DM1)**: An ADC consisting of trastuzumab linked to the microtubule-inhibiting agent DM1 (a maytansinoid). T-DM1 is approved for HER2-positive metastatic breast cancer and for residual disease after neoadjuvant therapy [10].
- **Trastuzumab Deruxtecan (T-DXd)**: An ADC consisting of trastuzumab linked to a topoisomerase I inhibitor (DXd) via a cleavable linker. T-DXd has a high drug-to-antibody ratio and demonstrates a potent bystander effect, enabling activity against tumors with heterogeneous or low HER2 expression [1, 2, 6].

### 6.2 Tyrosine Kinase Inhibitors (TKIs)

- **Lapatinib**: A reversible, dual inhibitor of EGFR and ERBB2. It binds to the ATP-binding pocket of the kinase domain. Resistance to lapatinib is a significant clinical challenge [3].
- **Neratinib**: An irreversible, pan-ErbB TKI that covalently binds to a cysteine residue in the kinase domain. It is effective against tumors with activating ERBB2 mutations, including L755S [4].
- **Tucatinib**: A highly selective, reversible inhibitor of ERBB2 kinase activity. It has shown efficacy in HER2-positive metastatic breast cancer, including brain metastases, and is used in combination with trastuzumab and capecitabine [4].

### 6.3 Investigational Agents and Novel Strategies

- **Small Molecule Transcription Factor Mimics**: Amphipathic isoxazolidines that mimic the activation domain of transcription factors have been shown to inhibit ERBB2 expression [5].
- **N-Carbobenzoxy-L-Phenylalanine**: A computational study suggests this compound disrupts ERBB2 homodimer formation, blocking autophosphorylation and downstream signaling [6].
- **Ibrutinib**: Computational studies suggest that ibrutinib, a BTK inhibitor, may act as a potent inhibitor of the HER2-L755S mutant [2].
- **CAR-T and CAR-Macrophage Therapy**: Engineered immune cells targeting ERBB2 are being developed for solid tumors, including brainstem glioma [15, 16].
- **Combination Therapies**: The complexity of the ERBB2 pathway suggests that drug synergy through combination therapy may be required to overcome resistance [7]. The co-amplification of ERBB2 with other oncogenes, such as GRB7, may influence therapeutic efficacy [17].

### 6.4 Pharmacogenomic Considerations

The efficacy of HER2-targeted therapies is influenced by the level of ERBB2 amplification and expression. Higher ERBB2 copy numbers are associated with improved response to trastuzumab in gastric cancer [11]. ERBB2 mRNA expression levels correlate with response to T-DM1 [10]. The presence of activating ERBB2 mutations can predict response to TKIs like neratinib [2, 17]. Conversely, mutations in the PI3K-AKT pathway (e.g., PIK3CA) or loss of PTEN can confer resistance to trastuzumab. The tumor immune microenvironment, including tumor-infiltrating lymphocytes (TILs) and immune-related gene expression signatures, also influences response to anti-HER2 therapy [8].

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL** |
| :--- | :--- | :--- |
| **NCBI Gene** | 2064 | https://www.ncbi.nlm.nih.gov/gene/2064 |
| **Ensembl** | ENSG00000141736 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141736 |
| **UniProt** | P04626 | https://www.uniprot.org/uniprotkb/P04626/entry |
| **RCSB PDB** | 1N8Z | https://www.rcsb.org/structure/1N8Z |
| **HGNC** | 3430 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430 |
| **OMIM** | 164870 | https://www.omim.org/entry/164870 |
| **ClinVar** | ERBB2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ERBB2%5Bgene%5D |
| **COSMIC** | ERBB2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ERBB2 |
| **STRING** | P04626 | https://string-db.org/network/9606.ENSP00000269571 |
| **BioGRID** | ERBB2 | https://thebiogrid.org/108555 |
| **Gene Ontology (GO)** | GO:0004713 (protein tyrosine kinase activity), GO:0007169 (transmembrane receptor protein tyrosine kinase signaling pathway), GO:0016021 (integral component of membrane) | https://www.ebi.ac.uk/QuickGO/ |

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Fernández-Martínez, A., Rediti, M., Tang, G., Pascual, T., Hoadley, K., Venet, D., Rashid, N., Spears, P. A., Islam, M. N., El-Abed, S., Bliss, J., Lambertini, M., Di Cosimo, S., Huobe, J., Goerlitz, D., Hu, R., Lucas, P. C., Swain, S. M., Sotiriou, C., Perou, C., & Carey, L. (2024). Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer. *JAMA Oncology*. URL: https://www.semanticscholar.org/paper/fdd3dbd92b23dbe555550cbf98c35dec8e7d422b

[2] Fernández-Martínez, A., Pascual, T., Singh, B., Nuciforo, P., Rashid, N., Ballman, K., Campbell, J., Hoadley, K., Spears, P., Paré, L., Brasó-Maristany, F., Chic, N., Krop, I., Partridge, A., Cortés, J., Llombart-Cussac, A., Prat, A., Perou, C., & Carey, L. (2023). Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer. *JAMA Oncology*. URL: https://www.semanticscholar.org/paper/f3ee74228f0f9b61905c8a56bca4bde713cbe7cf

[3] Gao, L., Shi, C., Yang, Z., Jing, W., Han, M., Zhang, J., Zhang, C., Tang, C., Dong, Y., Liu, Y., Chen, C., & Jiang, X. (2023). Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy. *Journal of Nanobiotechnology*. URL: https://www.semanticscholar.org/paper/46efb7950587ad5cbfbcc6d2a07a267efbc94385

[4] Nasioudis, D., Gysler, S., Latif, N., Cory, L., Giuntoli, R., Kim, S. H., Simpkins, F., Martin, L., & Ko, E. M. (2023). Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions. *Gynecologic Oncology*. URL: https://www.semanticscholar.org/paper/95b9a099e7e5c377f13db9faa6fe80b2e495efe8

[5] Kiefer, A., Prüfer, M., Röder, J., Pfeifer Serrahima, J., Bodden, M., Kühnel, I., Oberoi, P., & Wels, W. (2024). Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells. *Cells*. URL: https://www.semanticscholar.org/paper/bbc9335c21466e46779d83907d67980c0544faa6

[6] Manrai, P. A., McHenry, A., Sun, T., Santin, A., Ratner, E., Lin, D., Elvin, J., Hui, P., & Buza, N. (2024). Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations. *International Journal of Gynecological Pathology*. URL: https://www.semanticscholar.org/paper/e3dee8467090873a1c0fdfe110b17be986ceaa9f

[7] Lee, J., Franovic, A., Shiotsu, Y., Kim, S., Kim, K.-M., Banks, K., Raymond, V., & Lanman, R. (2019). Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. *Frontiers in Oncology*. URL: https://www.semanticscholar.org/paper/c652f39c5d1aabc0910bee1e0a195703dc438a21

[8] Lee, S., Toft, N. J., Axelsen, T. V., Espejo, M. S., Pedersen, T. M., Mele, M., Pedersen, H. L., Balling, E., Johansen, T., Burton, M., Thomassen, M., Vahl, P., Christiansen, P., & Boedtkjer, E. (2023). Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer. *Breast Cancer Research*. URL: https://www.semanticscholar.org/paper/05019098bbc2325d0e1582308513dbdf2e4ca5d8

[9] Albrecht, T., Rausch, M., Rössler, S., Albrecht, M., Braun, J. D., Geissler, V., Mehrabi, A., Vogel, M., Pathil-Warth, A., Mechtersheimer, G., Renner, M., Rupp, C., Weiss, K., Busch, E., Köhler, B., Springfeld, C., Schirmacher, P., & Goeppert, B. (2019). HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis. *BMC Cancer*. URL: https://www.semanticscholar.org/paper/e8d6c03d2dea34a0dce5a61c37bf1a14b3de0f18

[10] Albrecht, T., Rausch, M., Roessler, S., Geissler, V., Albrecht, M., Halske, C., Seifert, C., Renner, M., Singer, S., Mehrabi, A., Vogel, M., Pathil-Warth, A., Busch, E., Köhler, B., Rupp, C., Weiss, K., Springfeld, C., Röcken, C., Schirmacher, P., & Goeppert, B. (2019). HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. *Virchows Archiv*. URL: https://www.semanticscholar.org/paper/5a4ff1aaf0a16347a1a7b3f02803d9bb727f45d6

[11] Abdelhakeem, A., Wang, X., Rogers, J., Trail, A., Zhao, M., Blum-Murphy, M. A., Estrella, J. S., & Ajani, J. (2020). Outcomes of advanced gastroesophageal cancer patients with equivocal HER2 expression with or without ERBB2 gene amplification. *Oncology*. URL: https://www.semanticscholar.org/paper/27c3e0bbfc0f2e0b888ee6ab0ffeb700a58b5a22

[12] Uckun, F., & Qazi, S. (2023). Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes. *International Journal of Molecular Sciences*. URL: https://www.semanticscholar.org/paper/76805ddd320edf39c4500424243f7fb69bee389c

[13] Jodlowski, T., & Ramesh, K. (2019). Molecular Pathway and Fluorescence In Situ Hybridization Testing of ERBB2 (HER2) Gene Amplification in Invasive Ductal Carcinoma of Breast. *Molecular Diagnostics in Cancer Patients*. URL: https://www.semanticscholar.org/paper/4f3f65e77a0e8629d78af7a68fcbc1ef12c4c9ee

[14] Wen, W., Chen, W., Xiao, N., Bender, R., Ghazalpour, A., Tan, Z., Swensen, J., Millis, S., Basu, G., Gatalica, Z., & Press, M. (2015). Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers. *Journal of Molecular Diagnostics*. URL: https://www.semanticscholar.org/paper/72fbe72cfdc83e64ebc6effa657c14a3b52f228d

[15] Koshkin, V. S., Schafer, J. M., Scherrer, E., Boyiddle, C., Schwartz, N. R., Yu, H., Fang, Q., Baker, A. F., Sayedian, F. H., & Chan, E. (2025). Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma. *JCO Precision Oncology*. URL: https://www.semanticscholar.org/paper/05422195938ba9ebd86bbea95d88ec5f977c4bb1

[16] Kadowaki, S., Wakatsuki, T., Yamamoto, N., Ishizuka, N., Hironaka, S., Minashi, K., Hirano, H., Shoji, H., Yamaguchi, T., Chin, K., Ogura, M., Nakayama, I., Osumi, H., Ueki, A., Kitano, S., Boku, N., Yamaguchi, K., & Takahari, D. (2025). Relationship in gene amplification between ERBB2 and other oncogenes: Implications for the therapeutic efficacy of trastuzumab (Tmab)-based chemotherapy (CTx) in HER2 positive gastric cancer. *Journal of Clinical Oncology*. URL: https://www.semanticscholar.org/paper/c6038a2f04fd30fd60e282f8d132d81ab528b420

[17] Vernimmen, D., Begon, D., Salvador, S. C., Gofflot, M., Rosita, G., & Winkler. (N/A). Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. *Scientific Publication*. URL: https://www.semanticscholar.org/paper/8aaaa20e0fac039d8fceaf7fe9820f31c2ec3a15

[18] Braunstein, E. M., Chen, H., Juarez, F., Yang, F., Tao, L., Makhlin, I., Williams, D. M., Chaturvedi, S., Pallavajjala, A., Karantanos, T., Martin, R